On the final day of ASH there were many presentations of four-drug studies where Daratumumab has been added to backbone triplets for Newly Diagnosed, transplant-eligible patients. Daratumumab is a CD38 monoclonal antibody that binds with the CD38 receptor on myeloma cells. Here we look at two studies, one that is already generating change in the [...]
This post first appeared on Page Not Found - The Myeloma Crowd, please read the originial post: here
